Akums Drugs & Pharmaceuticals Ltd
About
Akums Drugs and Pharmaceuticals is an Indian company with a 10% market share in the Indian Contract Development and Market Organisation (CDMO) market as of FY24. It produces effective and safe formulations in multiple dosage forms like that of gummies, liquids, tablets, capsules, and powders. Akums’ services include formulation development, clinical trials, bioequivalence studies, and manufacturing and marketing new fixed-dose combinations and molecules. The company’s business is essentially divided into 4 verticals: nutraceuticals and Ayurveda, pharmaceuticals, cosmetics and derma, and active pharmaceutical ingredients ((APIs). With the help of partners like Apollo Pharmacy, Abbott, and GlaxoSmithKline, Akums is present in more than 60 countries around the world, including Vietnam, Latvia, Tanzania, Kenya, and more.
Featured In Fortune India Ranking
Financial Data 2023
Financial Data
| PARAMETERS | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 3721 -1.6% | 3782 35.5% | 2792 13.0% | 2470 229.4% | 750 13.4% | 662 -60.7% | 1683 12.1% | 1501 30.2% | 1153 41.6% | 815 24.4% | 655 11.0% | 590 41.0% | 418 9.3% | 383 - |
| Net Operating Income (INR Cr) | 3655 -0.46% | 3672 34.87% | 2723 12.78% | 2414 0.00% | 683 14.65% | 596 0.00% | 1651 12.75% | 1464 28.92% | 1136 0.00% | 794 22.22% | 650 14.17% | 569 38.46% | 411 8.87% | 377 14.87% |
| Profit (INR Cr) | 95 - | -253 - | 123 181.1% | 44 -41.7% | 75 10.5% | 68 10.2% | 61 42.7% | 43 -51.4% | 89 6.6% | 83 20.9% | 69 11.7% | 62 52.8% | 40 -7.6% | 44 - |
| Assets (INR Cr) | 2404 14.0% | 2109 28.1% | 1647 14.5% | 1439 56.6% | 919 11.4% | 825 -7.0% | 887 13.5% | 781 19.8% | 652 28.2% | 508 4.4% | 487 14.2% | 427 38.1% | 309 13.5% | 272 - |
| Net Worth (INR Cr) | 717 15.3% | 622 -29.7% | 885 22.5% | 722 0.0% | 842 9.7% | 767 0.0% | 629 27.4% | 494 7.8% | 458 0.0% | 431 23.9% | 348 24.6% | 279 28.3% | 218 22.7% | 177 31.3% |
| Employee Cost (INR Cr) | 590 16.2% | 508 19.6% | 425 -3.2% | 439 325.5% | 103 9.5% | 94 -70.1% | 315 17.3% | 268 54.0% | 174 130.0% | 76 16.3% | 65 33.1% | 49 54.2% | 32 10.4% | 29 - |
| Interest Cost (INR Cr) | 46 | 17 | 7 | 20 | 4 | 3 | 22 | 23 | 10 | 12 | 13 | 9 | 7 | 11 |
| Cash & Bank Balance (INR Cr) | 150 | 103 | 68 | 147 | 4 | 0 | 14 | 12 | 24 | 3 | 0 | 6 | 6 | 10 |
| Total Debt (INR Cr) | 619 | 395 | 130 | 175 | 51 | 33 | 213 | 255 | 166 | 56 | 136 | 147 | 91 | 95 |
Key Financial Ratios
| PARAMETERS | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 2.6% | - | 4.4% | 1.8% | 10.0% | 10.2% | 3.7% | 2.9% | 7.7% | 10.2% | 10.5% | 10.4% | 9.6% | 11.4% |
| Profit As % Of Assets | 4.0% | - | 7.5% | 3.0% | 8.2% | 8.2% | 6.9% | 5.5% | 13.6% | 16.3% | 14.1% | 14.4% | 13.0% | 16.0% |
| Profit As % Of Networth | 13.2% | - | 13.9% | 6.0% | 8.9% | 8.8% | 9.8% | 8.7% | 19.3% | 19.3% | 19.8% | 22.0% | 18.5% | 24.6% |
| Interest Cost to EBITDA % | 21.1% | - | 3.0% | 11.5% | 4.4% | 3.6% | 13.8% | 17.9% | 6.9% | 10.0% | 13.5% | 10.3% | 11.0% | 18.6% |
| Debt to Equity Ratio | 0.86 | 0.64 | 0.15 | 0.24 | 0.06 | 0.04 | 0.34 | 0.52 | 0.36 | 0.13 | 0.39 | 0.53 | 0.42 | 0.53 |
| RONW | 19.5% | - | 15.4% | 6.0% | 9.3% | 8.8% | 9.2% | 8.5% | 19.5% | 25.8% | 19.8% | 24.8% | 18.5% | 27.9% |
| ROCE | 11.7% | -9.4% | 11.6% | 9.3% | 13.3% | 13.0% | 14.3% | 14.3% | 20.8% | 27.6% | 20.5% | 24.0% | 19.4% | 24.1% |